Regeneron scores Eylea patent win against Mylan, keeping biosimilar at bay
Regeneron prevailed in a major patent fight against Mylan, staving off biosimilar competition for its flagship eye drug Eylea for another few years.
The big biotech first sued Mylan in August 2022, claiming that a proposed copy of Eylea infringed on the 11,084,865 patent. Mylan had filed for FDA approval in October 2021. Among other things, the ‘865 patent covers an ophthalmic formulation of a vascular endothelial growth factor (VEGF) antagonist suitable for intravitreal administration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
